
    
      This is a Phase 1b, open-label, adaptive design dose-ranging study to evaluate ADPKD
      biomarkers, PK, safety, tolerability, and pharmacodynamics (PD) of RGLS4326 administered via
      SC injection to patients with ADPKD. The goal is to assess the dose response relationship
      between RGLS4326 and ADPKD biomarkers. The study will consist of three sequential cohorts
      with approximately 18 to 27 subjects total.
    
  